News Release

Lessons to be learned from the latest science in Alzheimer’s research featured at 29th conference of Alzheimer’s Disease International

San Juan, Puerto Rico, 1 May 2014

“Latest Science” in Alzheimer’s disease current and future treatments and new data from the 10/66 research study is the focus of the first day’s plenary sessions at the 29th International Conference of Alzheimer’s Disease International (ADI), May 2, 2014 at the Sheraton Puerto Rico Hotel, San Juan, Puerto Rico.

Ivonne Jimenez, of the School of Medicine at the University of Puerto Rico, will present new findings from the 10/66 and EFIGA Study in Puerto Rico that reveal high prevalence of dementia observed in the area and a strong genetic component that warrants further evaluation and research.

Jose Luchsinger, of Columbia University Medical Center, New York, will review “Diabetes, Related Conditions and Alzheimer’s Disease” presenting evidence on the links between diabetes and Alzheimer’s disease and discussing potential mechanisms and therapeutic implications. This is of enormous public health importance because the prevalence of diabetes, insulin resistance, and obesity is increasing worldwide, particularly in the age group most at risk for Alzheimer’s disease.

“Improving Care for People with Dementia” is the day’s second important plenary session that will be discussed among experts.

Peter Lloyd-Sherlock, of the School of International Development, University of East Anglia, Norwich, UK is addressing “The Economic And Social Impacts On Households Providing Long-Term Care To Dependent Older People: Insights From The 10/66 Study”. Preliminary analysis of the results available to date demonstrates that incident care dependency due to dementia or other causes such as stroke can have important effects on household economic wellbeing and has a particularly large effect on female relatives and paid carers. This is of relevance to policy-makers with an interest in poverty reduction and gender equity.

“Case Management in Dementia” is presented by Noriyo Washizu, Alzheimer’s Association Japan, who will be sharing the experience including success, trial, and errors, which Japan had in the last 50 years, taking in the perspective of case management to contribute to a dementia friendly world.

An interesting panel discussion over “The Impact Of New Technology: Should You Be Informed Of Your Risk Of Developing Alzheimer's Disease?” will be presented on a plenary session on May 3.

Serge Gauthier, of McGill Center for Studies in Aging, Canada will cover the “Impact of new technology towards risk assessment for Alzheimer’s Disease”. In the same plenary, Helen Chiu of the Department of Psychiatry, Multi-Centre, Tai Po Hospital, Hong Kong will highlight the “Ethical issues in disclosing AD biomarkers”.

“Risk Factors And Prevention Of Dementia” will be the second plenary session of the day where Colin Masters, of Florey Institute, The University of Melbourne, Australia will cover how longitudinal cohort studies for genetic (familiar) and sporadic Alzheimer’s Disease define windows of preclinical therapeutic opportunity. 

On the same plenary topic, Laura Fratiglioni, of Aging Research Center, Karolinska Institutet and Stockholm University will present an overview on European studies on prevention of dementia.

On the day a satellite Symposium will focus on the “Support For Global Advocacy Of National Dementia Plans”.  On the last day of the conference the importance of this issue will be again highlighted in a plenary session themed Public Policy: The Power Of Advocacy And Alzheimer Plans where Gill Ayling, Deputy Director of Global Action Against Dementia at UK Department of Health will present “Prime Minister’s Dementia Challenge, UK And G8 Actions”.  We will also watch a video message from Norman Lamb, UK’s Health Minister for Care and Support.

For more information, visit


Notes to Editors

Media registration is complimentary for credentialed members of the media.

To qualify, you need an assignment letter from the organization for which you will be covering the conference (signed and on letterhead), along with professional identification for yourself as a journalist. For free registrations please contact, +44 (0) 845 1800 169. Please note that only two journalists from each media organization are entitled to the free registration.

About Alzheimer’s Disease International

ADI is the international federation of 79 Alzheimer associations throughout the world.  Each of our members is a non-profit Alzheimer association supporting people with dementia and their families.  ADI was founded in 1984 and registered as a non-profit organisation in the USA.  Based in London, ADI has been in official relations with the WHO since 1996 and has consultative status with the UN since 2012. 

ADI's vision is an improved quality of life for people with dementia and their families throughout the world. ADI believes that the key to winning the fight against dementia lies in a unique combination of global solutions and local knowledge. As such, it works locally, by empowering Alzheimer associations to promote and offer care and support for people with dementia and their carers, while working globally to focus attention on dementia and campaign for policy change from governments.

For more information, visit